Articles

Poll

Podcasts

Slideshows

Videos

Lopez discusses the growing prevalence of obesity in the US and the need for improved, cross-specialty care based on patients’ metabolic health.

Ana Maria Lopez, MD, MPH: The Current State of Obesity Care is ‘Woefully Deficient’

The American College of Physicians released new recommendations for the management of type 2 diabetes with inadequate glycemic control using metformin or other first-line therapies. 

ACP's New Type 2 Diabetes Guidance Recommends SGLT2is, GLP-1 RAs as Second-Line to Metformin

In this episode, hosts discuss the STEP HFpEF DM trial and the need for fair allocation of incretin-based therapies with ongoing shortages and overwhelming demand.

Diabetes Dialogue: STEP HFpEF DM and Fair Allocation of Incretin-Based Therapies

Topline data from the SURMOUNT-OSA studies provide insight into the effects of tirzepatide in OSA with obesity, with Lilly disclosing plans for a regulatory submission mid-year.

Tirzepatide Shows Benefit in Obstructive Sleep Apnea, SURMOUNT-OSA Trial

The STEP HFpEF DM trial at ACC.24 shows significant improvements in symptoms among patients with obesity-related HFpEF and diabetes mellitus. 

STEP HFpEF DM: Semaglutide 2.4 mg Improves Functional Status, Symptoms in Patients with Diabetes, HFpEF

A recap of the biggest FDA news and decisions in cardiovascular medicine from the first 3 months of 2024, with commentary on recent announcements by Deepak Bhatt, MD, MPH, MBA. 

Recapping Q1 2024 FDA Decisions in Cardiology, with Deepak Bhatt, MD, MPH, MBA

On March 07, 2024, Novo Nordisk provided updates on semaglutide 2.4 mg as well as the development programs cagrisema, monlunabant, and amycretin.

Novo Nordisk Delivers Updates on Development of Semaglutide, CagriSema, Amycretin, and More 

In our endocrinology month in review for February 2024, we are spotlighting trending studies and new data in endocrinology, the latest news surrounding tirzepatide, and a recap of the 4 episodes of our flagship endocrinology podcast launched during the last month.

Endocrinology Month in Review: February 2024

In this episode, hosts are joined by SURMOUNT-2 principal investigator Timothy Garvey, MD, to discuss the approval of the tirzepatide for chronic weight management, data from the SURMOUNT-2, -3, and 4 programs, the future of incretin therapies, and more. 

Diabetes Dialogue: Tirzepatide and the Future of Incretin Therapies, with Timothy Garvey, MD

In this episode, hosts are joined by co-chair of the SELECT steering committee A. Michael Lincoff, MD, to discuss results, potential explanations for cardiovascular benefit beyond weight reduction, FLOW trial implications, and the future of incretin therapies. 



Diabetes Dialogue: SELECT, Semaglutide, & the Future of Incretin Therapies, with A. Michael Lincoff, MD

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.